South KoreaHealthcare and life sciences2022 – ongoingJW Pharmaceutical
RAPTOR AI screening for additional immune-disease indications
JW Pharmaceutical reported positive immune-disease research data after RAPTOR AI screening
Problem
JW Pharmaceutical needed to identify additional diseases its drug candidates could treat. Indication research required substantial development time and expenditure.
Approach
JW Pharmaceutical began joint research with OncoCross in 2022, using its RAPTOR AI platform to screen potential indications. JW reported positive data for expanding its candidates into immune diseases and was preparing follow-up development plans. In May 2024, the partners agreed to extend their collaboration into oncology and regenerative medicine.
Results
No published figures
Takeaway
The reported result was research data supporting further development. It did not establish clinical efficacy in the additional indications.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Partner co-development
- Evidence
- Company's own claim
Sources
Source summaries
JW reported positive immune-disease indication-expansion data from its earlier OncoCross collaboration. It announced a further research agreement, without disclosing numerical research results.
Full details are in the original sources.